» Authors » Martin Kotrc

Martin Kotrc

Explore the profile of Martin Kotrc including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 35
Citations 457
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Monzo L, Jarolim P, Borlaug B, Benes J, Jurcova I, Jenca D, et al.
JACC Heart Fail . 2025 Jan; 13(2):315-329. PMID: 39797849
Background: Growth differentiation factor (GDF)-15 is a pleiotropic cytokine that is associated with appetite-suppressing effects and weight loss in patients with malignancy. Objectives: This study aims to investigate the relationships...
2.
Banovic M, Putnik S, da Costa B, Penicka M, Deja M, Kotrc M, et al.
Eur Heart J . 2024 Sep; 45(42):4526-4535. PMID: 39217448
Background And Aims: The question of when and how to treat truly asymptomatic patients with severe aortic stenosis (AS) and normal left ventricular (LV) systolic function is still subject to...
3.
Kubanek M, Binova J, Piherova L, Krebsova A, Kotrc M, Hartmannova H, et al.
ESC Heart Fail . 2024 Aug; 11(6):4127-4138. PMID: 39129193
Aims: Recent-onset dilated cardiomyopathy (RODCM) is characterized by heterogeneous aetiology and diverse clinical outcomes, with scarce data on genotype-phenotype correlates. Our aim was to correlate individual RODCM genotypes with left...
4.
Monzo L, Kovar J, Borlaug B, Benes J, Kotrc M, Kroupova K, et al.
Eur J Heart Fail . 2024 Jun; 26(9):1931-1940. PMID: 38853653
Aims: Patients with heart failure (HF) display metabolic alterations, including heightened ketogenesis, resulting in increased beta-hydroxybutyrate (β-OHB) formation. We aimed to investigate the determinants and prognostic impact of circulating β-OHB...
5.
Jenca D, Melenovsky V, Mrazkova J, Sramko M, Kotrc M, Zelizko M, et al.
Eur J Intern Med . 2024 May; 126:102-108. PMID: 38697863
Background: Data on the clinical significance of iron deficiency (ID) in patients with myocardial infarction (MI) are conflicting. This may be related to the use of various ID criteria. We...
6.
Wohlfahrt P, Jenca D, Melenovsky V, Stehlik J, Mrazkova J, Sramko M, et al.
Eur J Prev Cardiol . 2024 Mar; 31(14):1713-1720. PMID: 38497201
Aims: While heart failure (HF) symptoms are associated with adverse prognosis after myocardial infarction (MI), they are not routinely used for patients' stratification. The primary objective of this study was...
7.
Tykvartova T, Miklovic M, Kotrc M, Skaroupkova P, Kazdova L, Trnovska J, et al.
Pharmacol Res Perspect . 2024 Jan; 12(1):e1172. PMID: 38284173
While phosphodiesterase-5 inhibition (PED5i) may prevent hypertrophy and failure in pressure-overloaded heart in an experimental model, the impact of PDE5i on volume-overload (VO)-induced hypertrophy is unknown. It is also unclear...
8.
Wohlfahrt P, Jenca D, Melenovsky V, Stehlik J, Spertus J, Mrazkova J, et al.
J Am Heart Assoc . 2024 Jan; 13(2):e032505. PMID: 38193321
Background: Heart failure is a common complication after myocardial infarction (MI) and is associated with increased mortality. Whether remote heart failure symptoms assessment after MI can improve risk stratification is...
9.
Benes J, Kroupova K, Kotrc M, Petrak J, Jarolim P, Novosadova V, et al.
Sci Rep . 2023 Sep; 13(1):16004. PMID: 37749114
There is no biomarker reflecting right ventricular dysfunction in HFrEF patients used in clinical practice. We have aimed to look for a circulating marker of RV dysfunction employing a quantitative...
10.
Benes J, Kotrc M, Wohlfahrt P, Kroupova K, Tupy M, Kautzner J, et al.
Front Cardiovasc Med . 2023 Aug; 10:1194174. PMID: 37600032
Background: Right ventricular (RV) function is currently being evaluated solely according to the properties of RV myocardium. We have tested a concept that in patients with heart failure with reduced...